Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excedrin for “first-line” treatment

This article was originally published in The Tan Sheet

Executive Summary

Novartis is promoting Excedrin Migraine as "evidence-based medicine for the first-line treatment of migraine," according to a new print ad published in the May 24 issue of The Journal of the American Medical Association. As part of the firm's "First Line at the First Sign" advertising push, the ad includes statements such as, "clinically proven to provide early and powerful relief" and "statistically significant pain reduction seen as early as 30 minutes." The ad shows a bottle of Excedrin Migraine bursting through a doctor's prescription pad and states, "Powerful migraine efficacy with OTC convenience and safety." The UK's health body recently approved behind-the-counter sale of GlaxoSmithKline's Imigran Recovery (sumatriptan 50 mg) for migraine (1"The Tan Sheet" May 22, 2006, p. 3)...

You may also be interested in...



GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale

GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency

QUOTED. 19 February 2020. Stephen Hahn.

The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Topics

UsernamePublicRestriction

Register

PS099407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel